Amylyx Pharmaceuticals Inc(AMLX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:33 PM ET (Korea 10/31 05:33)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.43 | Insider Own | 15.31% | Shs Outstand | 111.4M | Perf Week | 6.1% |
| Market Cap | 3.62B | Forward P/E | - | EPS next Y | 24.33% | Insider Trans | -0.76% | Shs Float | 106.3M | Perf Month | 2.78% |
| Enterprise Value | 3.38B | PEG | - | EPS next Q | -0.38 | Inst Own | 85.67% | Short Float | 12.46% | Perf Quarter | 43.08% |
| Income | -0.15B | P/S | - | EPS this Y | 2.21% | Inst Trans | 0.47% | Short Ratio | 5.95 | Perf Half Y | 80.26% |
| Sales | 0.00B | P/B | 13.44 | EPS next 5Y | 49.92% | ROA | -66.25% | Short Interest | 13.25M | Perf YTD | 138.91% |
| Book/sh | 2.15 | P/C | 14.45 | EPS past 3/5Y | 19.94% -15.37% | ROE | -74.73% | 52W High | -29.85% ($41.14) | Perf Year | 105.41% |
| Cash/sh | 2 | P/FCF | - | Sales past 3/5Y | - | ROIC | -62.48% | 52W Low | 166.48% ($10.83) | Perf 3Y | 83.18% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 42.67% | Gross Margin | - | Volatility(W/M) | 4.59% 4.69% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 1.37 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 12.12 | EPS Q/Q | 16% | Profit Margin | - | RSI (14) | 51.89 | Recom | 1.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 12.12 | Sales Q/Q | - | SMA20 | 3.84% ($27.79) | Beta | -0.09 | Target Price | $42.64 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/8/6 | SMA50 | -6.58% ($30.89) | Rel Volume | 0.44 | Prev Close | $28.68 |
| Employees | 136 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | -8.06% - | SMA200 | 43.73% ($20.08) | Avg Volume(3M) | 2.23M | Price | $28.86 |
| IPO | 2022/1/7 | Option/Short | Yes/Yes | Trades | 12642 | Volume | 989,447 | Change | 0.63% |
A US clinical-stage biotech company developing treatments for neurological and metabolic rare diseases. It develops candidate therapies targeting neurodegenerative disorders and metabolic/endocrine rare diseases, with a pipeline spanning multiple indications and a solid funding base. A growth-stage biotech focused on unmet needs in neurological and metabolic rare diseases — a stock whose performance is driven by clinical progress and market sentiment.
Over the past 1 year, roughly in the middle
30% below its 1-year high.
Traded less than usual. That is 44% of its average volume.
AMLX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +2.2% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 3 years ago, your return today would be +83.2%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 85.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #17 of 83 in the industry
Based on market cap of $4B.
INDV#15 Indivior Pharmaceuticals Inc $4B PER 9.8 
LQDA#16 Liquidia Corp $4B PER 33.0 AMLX#17 Amylyx Pharmaceuticals Inc $4B PER - 
RGC#18 Regencell Bioscience Holdings Ltd $3B PER - 
BHC#19 Bausch Health Companies Inc $3B PER - 
FAQ
What kind of company is AMLX?
AMLX belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of AMLX?
The market cap of AMLX is approximately $3.6B, ranking 1,614 within its sector.
What is the 52-week high and low for AMLX?
AMLX has recorded a 52-week high of $41.14 and a low of $10.83.
